Table 3.
Treatment-emergent adverse events by products used
| TEAE | Soft-L (N=18)
|
Basic-L (N=72)
|
Extra/Intense-L (N=86)
|
Modélis-L (N=6)
|
Total (N=108)
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | m | n | % | m | n | % | m | n | % | m | n | % | m | |
| Patients with ≥1 TEAE | 8 | 44.4 | 11 | 36 | 50.0 | 84 | 41 | 47.7 | 114 | 2 | 33.3 | 3 | 52 | 48.1 | 212 |
| Injection-site erythema | 4 | 22.2 | 4 | 29 | 40.3 | 43 | 36 | 41.9 | 55 | 0 | 0.0 | 0 | 45 | 41.7 | 102 |
| Injection-site swelling | 2 | 11.1 | 2 | 20 | 27.8 | 29 | 25 | 29.1 | 42 | 2 | 33.3 | 2 | 36 | 33.3 | 75 |
| Injection-site bruising | 3 | 16.7 | 3 | 7 | 9.7 | 10 | 7 | 8.1 | 10 | 1 | 16.7 | 1 | 14 | 13.0 | 24 |
| Injection-site discoloration | 1 | 5.6 | 2 | 2 | 2.8 | 2 | 2 | 2.3 | 3 | 0 | 0.0 | 0 | 3 | 2.8 | 7 |
| Injection-site induration | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 3 | 3.5 | 4 | 0 | 0.0 | 0 | 3 | 2.8 | 4 |
Note: n, number of patients who experienced ≥1 TEAE; m, number of TEAEs.
Abbreviations: Soft-L, Soft Lidocaine; Basic-L; Basic Lidocaine; Extra/Intense-L, Extra/Intense Lidocaine; Modélis-L, Modélis® Shape Lidocaine; TEAE, treatment-emergent adverse event.